Dr Matthew Hobbs, director of research at Prostate Cancer UK, said there is an urgent need for better prostate cancer testing ...

Research has found the PSA prostate cancer test for people without symptoms has only led to a small reduction in deaths ... currently missed and do even less harm,” he said.

Pfizer Inc. today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide ...

Alerts delivered via the electronic health record temporarily reduces unnecessary screening and treatment but does not create ...

An analysis of prostate cancer trends in California revealed an unexpected spike in distant-stage disease cases between 2011 and 2021.Meanwhile, prostate cancer mortality — which had been on the ...

Harm reduction advocates are implementing solidarity-based strategies for curbing drug overdoses in Minneapolis. This story was copublished and supported by the journalism nonprofit the Economic ...

The FDA approved Bimzelx, an IL-17A/IL-17F inhibitor, for use in active PsA in September 2024, adding to the authorization that UCB secured in plaque psoriasis 11 months earlier. Last month ...

Harm reduction, frequently misunderstood, offers more than a pragmatic intervention; it represents a relational strategy rooted in attachment theory. As a result, some of the most important work a ...